Medicines with Valsartan for hypertension should not be consumed, warns the MSP – Printed edition



[ad_1]

Health Surveillance warned that drugs with the active ingredient Valsaltán (from China), which is used for products for high blood pressure should be removed immediately, because there is an international warning that the aforementioned component is contaminated and its consumption This can cause cancer. In Paraguay, there are 91 lots that must be removed from circulation and destroyed.

The National Directorate of Sanitary Vigilance reported Friday evening that drugs with the active ingredient Valsartan, from Zhejing Huahai, Lindai, China, will be withdrawn from the market and destroyed, following an international alert issued by the Spanish Agency in a preventive manner and considering that this situation represents a risk to health.

It was discovered that the aforementioned active ingredient of the Chinese company contained impurities that could cause cancer with its intake.

According to the alert, the affected lots were contaminated by an impurity generated during a change in the manufacturing process.

There are 91 affected lots

According to information provided by the Ministry of Public Health (MSP), in Paraguay, 91 lots are affected by the measure, which makes 31 types of products from four laboratories, which are: Almos SA (for its product Tensional in different presentations), Mather Company SRL (for its product Valaplex, in different presentations), Abbott-Pharma International (for its product Vartalán in its various presentations) and Roemmers SACI (Ampliron, in its various presentations).

Valsartan is an active ingredient that is commonly found in medications administered to patients with hypertension.

It is also used to reduce the risk of heart attack, as well as heart failure or heart attacks. It works as a vasodilator helping to control blood pressure.

According to data, in Paraguay, the prevalence of hypertension in adults is 45%, an increasing trend and that is the main risk factor associated with 50% of myocardial infarction and 60% of the stroke.

Given the high number of people suffering from this disease, the drugs for it have a high turnover rate.

[ad_2]
Source link